Compare Vaxcyte Inc. Common Stock (PCVX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Snap Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Snap Inc trades at $6.05 (market cap $10.98B). The key difference: Vaxcyte Inc. Common Stock and Snap Inc are close in size by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Snap Inc for 68 Days on average.
| PCVX | SNAP | |
|---|---|---|
Market Cap | $10.51B | $10.98B |
Volume | 2,644,694 | 53,140,165 |
Sector | Health | Media |
52-Week High | $73.82 | $9.09 |
52-Week Low | $40.32 | $3.93 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $9.14B | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Snap Inc. (SNAP) trades at $6.10, down 6.73% over 24 hours, with technical indicators showing a bullish trend despite overbought RSI signals. The company reported revenue growth to $5.93B in 2025, though net losses persist at -$460M, with improving margins. Recent news highlights AI and AR developments, including SPECS glasses partnerships with NVIDIA and Salesforce, driving investor optimism amid regulatory pressures.
The outlook remains cautious; while analyst consensus is a $7.91 price target with 38% buy ratings, risks include sustained losses, high debt, and competitive threats. Upside hinges on monetizing AI innovations and achieving profitability, but volatility from sentiment shifts poses near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
